Achiko AG Production and Sales Update
21 déc. 2022 07h42 HE
|
Achiko AG
AptameX™ Gen 2 Covid-19 rapid calibration outperforms Abbott Pan Bio and Clugene’s rapid tests in Indonesia in validation tests.Sample of 20 PCR Positive and 9 Negative samples, indicated a 100% match...
Achiko AG Reports First Half to June 30, 2022 Results and Provides Corporate Update as of September 30, 2022
03 oct. 2022 07h33 HE
|
Achiko AG
Achiko reports an EBITDA loss of USD $1.9 million, compared to an EBITDA loss of USD $4.6 million for the six months ending June 30, 2021.Focal points of the first half year were completion of a major...
Achiko AG Announces Annual Results for the Year Ended December 31, 2021
26 juin 2022 19h30 HE
|
Achiko AG
ZURICH, Switzerland, June 26, 2022 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces its financial results for the year ended December...
Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to Occur by June 10, 2022
06 juin 2022 07h40 HE
|
Achiko AG
ZURICH, Switzerland, June 06, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that...
Achiko AG Publication of Annual Report and Annual Financial Statements 2021 to Occur by June 6, 2022
31 mai 2022 07h30 HE
|
Achiko AG
ZURICH, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces that...
Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to Occur by May 31, 2022
29 avr. 2022 07h30 HE
|
Achiko AG
ZURICH, Switzerland, April 29, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that...
AptameX Production and Commercialization Update
28 avr. 2022 08h15 HE
|
Achiko AG
Company has commenced shipping and will book first sales in May 2022Reorganized production line able to meet stronger than expected demand for Achiko AG’s innovative DNA aptamer saliva-based rapid...
Achiko AG Looks Back at Pivotal Year and Reaffirms Commitment to Provide Affordable and Accurate COVID-19 Testing Solution
23 déc. 2021 07h30 HE
|
Achiko AG
2021 Was a Pivotal Year for Achiko, Marked by Seminal Developments and ApprovalsWith AptameX™, Achiko Launched an Innovative DNA Aptamer Saliva-Based Rapid Test for Covid-19 as an Affordable and...
Achiko AG’s Shares Begin Trading on the OTCQB Market
20 déc. 2021 07h30 HE
|
Achiko AG
ZURICH, Switzerland, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468; www.achiko.com) (“Achiko”, the “Company”), a global healthtech company which has...
Market Outlook and Production Plan Update for AptameX
20 oct. 2021 07h30 HE
|
Achiko AG
After receiving product and registration approval from Indonesia’s Ministry of Health in August, Achiko is positioned to produce up to a million AptameX test kits in Q4 2021, and more if the supply...